IDXX IDEXX LABORATORIES INC /DE
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%
Margins
Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%
Returns
ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Cost of revenue | $1.64B | $1.52B | $1.47B | $1.36B | $1.33B |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B |
| R&D expense | $251.21M | $219.79M | $190.95M | $254.82M | $161.01M |
| SG&A expense | $404.79M | $442.29M | $335.82M | $326.25M | $309.66M |
| Operating income | $1.36B | $1.13B | $1.10B | $898.76M | $932.03M |
| Interest expense | $38.85M | $31.20M | $41.58M | $39.86M | $29.81M |
| Pretax income | $1.32B | $1.11B | $1.06B | $859.97M | $902.65M |
| Income tax | $264.73M | $221.96M | $216.13M | $180.88M | $157.81M |
| Net income | $1.06B | $887.87M | $845.04M | $679.09M | $744.85M |
| EBITDA | $1.51B | $1.26B | $1.21B | $1.01B | $1.04B |
| EPS (basic) | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 |
| EPS (diluted) | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 |
| Weighted avg. shares (diluted) | 81.03M | 83.25M | 83.98M | 84.60M | 86.57M |
| Banking | |||||
| Provision for credit losses | $8.43M | $6.87M | $5.55M | $5.83M | $1.48M |
| Balance sheet | |||||
| Cash & equivalents | $180.07M | $288.27M | $453.93M | $112.55M | $144.45M |
| Receivables | $552.38M | $473.57M | $457.44M | $400.62M | $368.35M |
| Inventory | $377.76M | $381.88M | $380.28M | $367.82M | $269.03M |
| Current assets | $1.41B | $1.40B | $1.50B | $1.10B | $955.65M |
| PP&E, net | $747.38M | $713.12M | $702.18M | $649.47M | $587.67M |
| Goodwill | $414.00M | $405.10M | $366.00M | $361.80M | $359.35M |
| Intangibles | $109.84M | $111.68M | $84.50M | $97.67M | $99.03M |
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B |
| Current liabilities | $1.15B | $1.07B | $951.55M | $1.24B | $763.58M |
| Short-term debt | $75.00M | $167.79M | $75.00M | $74.98M | $75.00M |
| Long-term debt | $374.84M | $449.79M | $622.88M | $694.39M | $775.21M |
| Total debt | $449.84M | $617.57M | $697.88M | $769.37M | $850.20M |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B |
| Shareholders' equity | $1.61B | $1.60B | $1.48B | $608.74M | $689.99M |
| Net debt | $269.77M | $329.31M | $243.95M | $656.82M | $705.75M |
| Shares outstanding | 79.71M | 81.60M | 83.03M | 82.89M | 84.56M |
| Cash flow statement | |||||
| Operating cash flow | $1.18B | $929.00M | $906.51M | $542.98M | $755.55M |
| Capital expenditure | $124.68M | $120.92M | $133.63M | $148.84M | $119.55M |
| Free cash flow | $1.06B | $808.08M | $772.88M | $394.15M | $636.00M |
| Investing cash flow | -$136.24M | -$207.06M | -$125.25M | -$195.35M | -$292.97M |
| Financing cash flow | -$1.16B | -$878.07M | -$442.00M | -$370.94M | -$697.41M |
| Depreciation & amortization | $145.18M | $129.94M | $114.91M | $111.90M | $104.60M |
| Stock-based compensation | $60.01M | $60.30M | $59.74M | $49.77M | $37.76M |
| Share buybacks | $1.22B | $837.03M | $71.92M | $819.71M | $746.78M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.